BPH gene expression profile associated to prostate gland volume

Diagnostic Molecular Pathology

Volumn 17, Issue 4, 2008, Pages 207-213

  Descazeaud, Aurelien ^a,b,c,h   Rubin, Mark A ^d,e,f,g   Hofer, Matthias ^d,e,f,g   Setlur, Sunita ^d,e,f,g   Nikolaief, Nathalie ^a,b   Vacherot, Francis ^a,b   Soyeux, Pascale ^c   Kheuang, Laurence ^a,b   Abbou, Claude C ^a,b,c   Allory, Yves ^a,b,c   De La Taille, Alexandre ^a,b,c  

^a INSERM U955   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Benign prostatic hyperplasia; Gene expression; Prostate volume

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; RNA;

AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; GENE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE PROBE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; ORGAN SIZE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; RNA EXTRACTION;

AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; UP-REGULATION;

EID: 57649120002     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31816f6352     Document Type: Article

References (31)

1. Nickel JC. Benign prostatic hyperplasia: does prostate size matter? Rev Urol. 2003;5(suppl 4):12-17.
2. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol. 2000;199:65-116.
3. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98;5116-5121.
4. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863-14868.
5. Lepor H. Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate. 1990;(suppl 3):75-84.
6. Vaughan ED. Long-term experience with 5-alpha-reductase inhibitors. Rev Urol. 2003;5(suppl 5):22-27.
7. Quayle SN, Sadar MD. A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics. 2006;87:633-637.
8. Scorilas A, Gregorakis AK. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy. Biol Chem. 2006;387:789-793.
9. Jung C, Kim RS, Zhang HJ, et al. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 2004;64:9185-9192.
10. Festuccia C, Muzi P, Gravina GL, et al. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol. 2007;30:193-200.
11. Sun X, Chen C, Vessella RL, et al. Microsatellite instability and mismatch repair target gene mutations in cell lines and xenografts of prostate cancer. Prostate. 2006;66:660-666.
12. Jariwala U, Prescott J, Jia L, et al. Identification of novel androgen receptor target genes in prostate cancer. Mol Cancer. 2007;6:39.
13. Wilson MJ, Haller R, Li SY, et al. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol. 2005;174:1124-1128.
14. Bullard RS, Gibson W, Bose SK, et al. Functional analysis of the host defense peptide human beta defensin-1: new insight into its potential role in cancer. Mol Immunol. 2008;45:839-848.
15. Schmidt RJ, Zhang Y, Zhao Y, et al. A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol. 2008. In press.
16. Harper ME, Glynne-Jones E, Goddard L, et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate. 1992;20:243-253.
17. Phillips SM, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer. 1994;70:1252-1257.
18. Zeng L, Rowland RG, Lele SM, et al. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol. 2004;35:290-297.
19. McCulloch DR, Akl P, Samaratunga H, et al. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res. 2004;10:314-323.
20. Sakamoto S, Yokoyama M, Prakash K, et al. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. J Biomol Screen. 2003;8:701-711.
21. Tiniakos DG, Mitropoulos D, Kyroudi-Voulgari A, et al. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate. Urology. 2006;67:204-208.
22. Shariat SF, Ashfaq R, Roehrborn CG, et al. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol. 2005;174:2046-2050.
23. Bozec A, Ruffion A, Decaussin M, et al. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab. 2005;90:17-25.
24. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53:1423-1432.
25. Soulitzis N, Karyotis I, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol. 2006;29:305-314.
26. Roehrborn CG. 5-alpha-reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol. 2003;5(suppl 5):12-21.
27. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000;60:4550-4555.
28. Fromont G, Chene L, Latil A, et al. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase- polymerase chain reaction approach. J Urol. 2004;172:1382-1385.
29. Luo J, Dunn T, Ewing C, et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate. 2002;51:189-200.
30. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202-1216.
31. Prakash K, Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA. 2002;99:7598-7603.